Trial Profile
Phase II trial of IMO-8400 in patients with Duchenne muscular dystrophy
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Bazlitoran (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 10 Mar 2016 According to an Idera Pharmaceuticals media release, status changed from planning to suspended.
- 24 Mar 2015 New trial record